|  Keyword Search
| Date | Title | | | 11/12/09 | MDRNA, Inc. Receives NASDAQ Notification| BOTHELL, WA, Nov 12, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that on November 6, 2009
it received a letter from The NASDAQ Stock Market, Inc. notifying the
Company that, for ten consecutive business days, based on the
Company's Market Value of Listed Securities (MVLS), it did not comply
with the $50 million minimum MVLS for continued listing on The NASDAQ
Global Market set forth in NASDAQ Marketplace Rule 5450(b)(3)(A). The
Company has a grace period of 9... |
|  | | 11/12/09 | MDRNA, Inc. Announces Third Quarter 2009 Financial Results| Highlights Third Quarter and Recent Corporate Accomplishments BOTHELL, WA, Nov 12, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) today reported financial results for the
three- and nine-month periods ended September 30, 2009. Net loss for
the third quarter of 2009 was approximately $7.0 million or $0.17 per
share, compared to a net loss of approximately $16.1 million or $0.52
per share for the same period of 2008. The net loss for the nine
months ended September 30, 2009 wa... |
| | | 11/05/09 | MDRNA, Inc. to Hold Third Quarter 2009 Results Conference Call on Thursday, November 12, 2009 at 4:30 pm Eastern Time| BOTHELL, WA, Nov 05, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a
conference call with investors and security analysts on Thursday,
November 12, 2009, at 4:30 pm Eastern Time (1:30 pm Pacific Time) to
provide a business update and discuss financial results for the 3rd
quarter ended September 30, 2009. To participate in the live
conference call, U.S. residents should dial 866-543-6405 and
international callers should dial 617-213-8897. The p... |
| | | 10/29/09 | MDRNA to Present Data on Tumor Reduction at Cancer Therapy Conference| Results Demonstrate Sustained Reduction in Liver and Bladder Tumor Growth via RNAi Mediated Knockdown of SurvivinBOTHELL, WA, Oct 29, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced the presentation of data related
to its RNAi oncology programs at the 24th Annual Meeting of the
International Society for Biological Therapy of Cancer, taking place
October 28-31, 2009 at the Gaylord National Hotel and Conve... |
| | | 10/22/09 | MDRNA to Present at the 8th Annual BIO Investor Forum| BOTHELL, WA, Oct 22, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced that J. Michael French, MDRNA's
President and Chief Executive Officer, will deliver a corporate
presentation and business update at the 8th Annual BIO Investor
Forum. The presentation will take place on Thursday, October 29,
2009 at 9:00am Pacific Time (12:00pm Eastern Time) at the Palace
Hotel in San Francisco, California.
To acces... |
| | | 10/12/09 | MDRNA Reports UsiRNA Reduces Tumor Growth In Vivo| Demonstrates RNAi-Mediated Knockdown of Previously "Non-Druggable" Targets in Liver and Bladder Cancers BOTHELL, WA, Oct 12, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today presented new in vivo data demonstrating
continued progress in the advancement of the Company's oncology
program. J. Michael French, President and CEO, reported that MDRNA's
UsiRNAs, delivered by the Company's DiLA2 platform, down-regulated... |
| | | 09/29/09 | MDRNA Announces Patent Allowance Covering an siRNA With Therapeutic Potential for Oncology and Other Indications| siRNA Directed Against JAM-1 Gene Also Has Potent Drug Delivery Potential BOTHELL, WA, Sep 29, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced that the U.S. Patent and
Trademark Office (USPTO) has issued a Notice of Allowance for patent
application U.S. 11/624,630 covering an siRNA directed against a
junctional adhesion molecule-1 (JAM-1) gene.
The siRNA of the allowed claim has a broad array of pot... |
| | | 09/08/09 | MDRNA Adds June D. Ameen to Management Team as Vice President, Corporate Development| BOTHELL, WA, Sep 08, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that June D. Ameen, RN,
MBA, will join the Company as Vice President, Corporate Development
reporting to the President & CEO. Ms. Ameen will lead the alliance
management, business development, technology evaluation and strategic
partnering efforts for the Company.
"We are extremely pleased to have June join our management team,"
said Michael French, President and CEO at MDRNA. "Recently, we enga... |
| | | 09/03/09 | MDRNA, Inc. to Present at the Rodman & Renshaw 11th Annual Healthcare Conference| MDRNA to Also Participate on a Panel of Leading RNAi Companies BOTHELL, WA, Sep 03, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will present at
the Rodman & Renshaw 11th Annual Healthcare Conference on Thursday,
September 10, 2009, at 9:10 a.m. Eastern Time (6:10 a.m. Pacific
Time) at the New York Palace Hotel in New York City. J. Michael
French, MDRNA's President and Chief Executive Officer, will present a
corporate overview and business updat... |
| | | 08/11/09 | MDRNA, Inc. Appoints James M. Karis to Its Board of Directors| BOTHELL, WA, Aug 11, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that James M. Karis has
been appointed to the Company's Board of Directors. His appointment
brings the number of MDRNA board members to six.
"I am pleased to welcome James Karis to MDRNA's Board of Directors,"
stated Bruce R. Thaw, Chairman of the Board of Directors. "James has
spent 30 years in the pharmaceutical, healthcare services and medical
device industries and brings extensive corporate ... |
| | | 08/06/09 | MDRNA, Inc. to Present at the 29th Canaccord Adams Global Growth Conference| BOTHELL, WA, Aug 06, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will present at
the 29th annual Canaccord Adams Global Growth Conference on
Wednesday, August 12, 2009, at 3:00 p.m. Eastern Time (12:00 p.m.
Pacific Time) at the InterContinental Hotel in Boston, Massachusetts.
J. Michael French, MDRNA's President and Chief Executive Officer,
will present a corporate overview and business update.
To access the live audio webcast for this conference, pl... |
| | | 08/03/09 | MDRNA, Inc. Reports Positive In Vivo Data Demonstrating That Its UsiRNAs Are Highly Potent Against Metabolic and Oncology Targets| UsiRNAs Work Via the RNAi Mechanism of Action but With Minimal Off-Target Activity BOTHELL, WA, Aug 03, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today positive data on its
proprietary UsiRNA technology, demonstrating that its UsiRNAs are
highly potent against metabolic disease and cancer targets in rodent
models. Further, the data establish that the knockdown of these
targets is achieved via an RNAi-mediated process. Of particular
importance is that the data ... |
| | | 07/29/09 | MDRNA, Inc. Announces Second Quarter 2009 Financial Results| BOTHELL, WA, Jul 29, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) today reported financial results for the
three- and six-month periods ended June 30, 2009. Net loss for the
second quarter of 2009 was approximately $7.5 million or $0.21 per
share, compared to a net loss of approximately $14.3 million or $0.48
per share for the same period of 2008. The net loss for the six
months ended June 30, 2009 was approximately $0.3 million or $0.01
per share, compared to approximately $... |
| | | 07/29/09 | MDRNA, Inc. to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference| BOTHELL, WA, Jul 29, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will present at
the BMO Capital Markets 9th Annual Focus on Healthcare Conference on
Wednesday, August 5, 2009, at 2:15 p.m. Eastern Time (11:15 a.m.
Pacific Time) at the Millennium Broadway Hotel in New York City. J.
Michael French, MDRNA's President and Chief Executive Officer, will
present a corporate overview and business update.
To access the live audio webcast for this conference,... |
| | | 07/23/09 | MDRNA, Inc. to Hold Second Quarter 2009 Results Conference Call on Thursday, July 30, 2009, at 8:30 a.m. Eastern Time| BOTHELL, WA, Jul 23, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a
conference call with investors and security analysts on Thursday,
July 30, 2009, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to
provide a business update and discuss financial results for the 2nd
quarter ended June 30, 2009. To participate in the live conference
call, U.S. residents should dial 800-510-9836 and international
callers should dial 617-614-3670. The partic... |
| | | 07/14/09 | MDRNA Appoints New Chief Financial Officer| BOTHELL, WA, Jul 14, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today the appointment of Peter
S. Garcia as Chief Financial Officer and Secretary, reporting to the
President and CEO. Mr. Garcia will lead and direct corporate
financial and financing activities, investor and public relations
efforts, as well as facilities and information technology operations
for the Company.
"We are extremely pleased to add an individual of Pete's caliber to
our management team,"... |
| | | 06/23/09 | MDRNA, Inc. Regains Full Compliance With All Marketplace Rules to Remain on the NASDAQ Global Market| Receives Letter From NASDAQ Regarding Compliance With NASDAQ Marketplace Rule 5450(b)(2)(A)BOTHELL, WA, Jun 23, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that on June 22, 2009,
it received a letter from The NASDAQ Stock Market, LLC notifying the
Company that it has regained full compliance with all requirements
for remaining on The NASDAQ Global Market, specifically NASDAQ
Marketplace Rule 5450(b)(2) (the "market value standard"), which
requires, among othe... |
| | | 06/19/09 | MDRNA, Inc. Gains Full Financial and Transactional Control of Its Proprietary UNA Technology| Amends Agreement With RiboTask to Eliminate All Milestone and Royalty PaymentsBOTHELL, WA, Jun 19, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it now has full
financial and transactional control over the use of its proprietary
UNA (Unlocked Nucleobase Analog) technology for the development of
RNAi-based therapeutics. The Company completed negotiations with
RiboTask ApS to eliminate all downstream financial consideration to
RiboTask resulting from collabo... |
| | | 06/16/09 | MDRNA, Inc. Announces Full Repayment of GE Capital Debt| BOTHELL, WA, Jun 16, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has repaid all of
its remaining debt to General Electric Capital Corporation (GECC)
under the January 2009 Loan and Security Agreement.
"I am pleased we have met our commitment to shareholders to eliminate
the Company's remaining term debt obligations prior to the start of
the third quarter," stated J. Michael French, President and CEO. "In
less than five months time, we retired a $5.5 m... |
| | | 06/12/09 | MDRNA, Inc. Announces Closing of $10.5 Million Registered Direct Financing| BOTHELL, WA, Jun 12, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has closed its
previously announced sale of 5.25 million shares of its common stock
and warrants to purchase 5.25 million shares of its common stock for
gross proceeds of $10.5 million. MDRNA sold the shares for $2.00 per
share. The exercise price of the warrants is $2.38 per share. The
warrants, with a five and a half year term, will be exercisable six
months from June 12, 2009. MDRNA p... |
| | | 06/11/09 | MDRNA, Inc. Granted Request to Remain Listed on The NASDAQ Global Market| BOTHELL, WA, Jun 11, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that on Wednesday, June
10, 2009, the NASDAQ Hearings Panel granted the request of the
Company to remain listed on The NASDAQ Global Market and that the
Company had until August 31, 2009 to establish a minimum $10.0
million in stockholders' equity or demonstrate compliance with one of
the alternative listing criteria per NASDAQ Marketplace Rule 5450(b).
The Company announced on March 6, 2009 tha... |
| | | 06/10/09 | MDRNA, Inc. Raises $10.5 Million in Registered Direct Offering| BOTHELL, WA, Jun 10, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it entered into
definitive agreements on June 9, 2009 with existing investors to
raise gross proceeds of $10.5 million though a registered direct
offering. Under terms of the agreements, the Company will sell 5.25
million shares of its common stock at $2.00 per share. As part of the
transaction, the investors also will receive warrants, with a five
and a half year term, to purchase 5.25 mil... |
| | | 06/09/09 | MDRNA, Inc. Receives Full FDA Approval of Generic Calcitonin-Salmon Nasal Spray for Osteoporosis| Par Pharmaceutical Companies, Inc. Launches ProductBOTHELL, WA, Jun 09, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has obtained full
U.S. Food and Drug Administration (FDA) approval of its Abbreviated
New Drug Application (ANDA) for generic calcitonin-salmon nasal spray
for the treatment of osteoporosis and that Par Pharmaceutical
Companies, Inc. (NYSE: PAR) has launched the product.
Calcitonin-salmon nasal spray, a legacy product developed by MDRNA i... |
| | | 06/08/09 | MDRNA, Inc. Reports Effective Local Delivery of a UsiRNA in an In Vivo Model of Bladder Cancer| Improved Performance of the DiLA2 siRNA Delivery Platform With Proprietary Peptide NanoparticlesBOTHELL, WA, Jun 08, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today in vivo data from a
bladder cancer model demonstrating effective localized delivery of a
UsiRNA to a solid tumor, thus further expanding the delivery
capabilities of the DiLA2 Platform. In addition, the Company reported
in vivo data demonstrating the ability of its proprietary
peptide-based nanoparticl... |
| | | 05/26/09 | MDRNA, Inc. Regains Compliance With NASDAQ Marketplace Rule 5450(a)(1)| BOTHELL, WA, May 26, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has received a
letter from the Listing Qualifications Department of The NASDAQ Stock
Market notifying the Company that because the closing bid price of
its common stock has been at or above $1.00 per share for at least
ten consecutive trading days, it has regained compliance with NASDAQ
Marketplace Rule 5450(a)(1) (formerly Marketplace Rule 4450(a)(5)).
"We are pleased to have regained c... |
| | | 05/21/09 | MDRNA, Inc. Resizes Board of Directors| BOTHELL, WA, May 21, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that as a result of its
2009 annual meeting on May 20, 2009, it has resized its Board of
Directors to establish a five person Board consistent with the
Company's cost containment efforts and overall focus as an RNAi drug
discovery and pre-clinical biotech company. The new Board of
Directors, effective immediately, will consist of Bruce R. Thaw, Esq.,
Chairman of the Board; Daniel Peters; James E... |
| | | 05/19/09 | MDRNA Reports Its Proprietary RNAi-Based Compounds Are Well Tolerated and Demonstrate High Potency Against Multiple Targets in Preclinical Studies| Data Confirm 90% Knockdown of Factor VII at 1 mg/kg With Duration of Effect up to 28 DaysBOTHELL, WA, May 19, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today positive in vivo efficacy
data showing that its proprietary UsiRNA constructs are highly potent
and highly specific against ApoB and Factor VII message. The data are
being presented today by Michael V. Templin, Ph.D., Vice President,
Discovery Research and Pharmaceutical Development of MDRNA, at the
TIDES Oli... |
| | | 05/15/09 | MDRNA, Inc. Appoints Beverly L. Davidson, Ph.D. and Carl Novina, M.D., Ph.D., to Its Scientific Advisory Board| BOTHELL, WA, May 15, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today the appointment of
Beverly L. Davidson, Ph.D., and Carl Novina, M.D., Ph.D., to its
Scientific Advisory Board (SAB).
"The appointment of these outstanding scientists and opinion leaders
to our Scientific Advisory Board reflects our strong commitment to
scientific excellence as a premier RNAi therapeutics company," stated
Barry Polisky, Ph.D., Chief Scientific Officer. "We are particularly
pleas... |
| | | 05/14/09 | MDRNA, Inc. Announces First Quarter 2009 Financial Results| BOTHELL, WA, May 14, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) today reported financial results for the
first quarter ended March 31, 2009.
"The first quarter of 2009 was a period of significant accomplishment
for the Company," stated J. Michael French, President and Chief
Executive Officer. "With the sale of our intranasal contract
manufacturing operations in Hauppauge, N.Y. on March 31st, we
completed our transition from a clinical stage delivery company to a
pre-clinic... |
| | | 05/11/09 | MDRNA, Inc. to Hold First Quarter 2009 Earnings Conference Call on Friday, May 15, 2009, at 8:30 a.m. Eastern Time| BOTHELL, WA, May 11, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a
conference call with investors and security analysts on Friday, May
15, 2009, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to
discuss financial results for the first quarter ended March 31, 2009.
To participate in the live conference call, U.S. residents should dial
866-761-0748 and international callers should dial 617-614-2706. The
participant passcode for the live co... |
| | | 04/10/09 | MDRNA, Inc. Complies With NASDAQ Marketplace Rule 4350(b)(1)(B)| BOTHELL, WA, Apr 10, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that the Company's
independent registered public accounting firm included an explanatory
paragraph in their opinion on the Company's financial statements
included in the recently filed Annual Report on Form 10-K for the
year ended December 31, 2008, relating to the Company's ability to
continue as a going concern.
"As we described in our fourth quarter earnings call, we expected to
receive the... |
| | | 04/01/09 | MDRNA, Inc. Sells Contract Manufacturing Operation| Company Eliminates Cash Burn Related to Non-RNAi OperationsBOTHELL, WA, Apr 01, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has entered into
an Asset Purchase Agreement with Par Pharmaceutical, Inc. (NYSE: PRX)
under which Par will acquire the Company's manufacturing facilities
in Hauppauge, New York as well as the Company's Abbreviated New Drug
Application (ANDA) for generic calcitonin-salmon nasal spray. Under
the terms of the Agreement, MDRNA will ... |
| | | 03/24/09 | MDRNA, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results| BOTHELL, WA, Mar 24, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) today reported financial results for the
fourth quarter and year ended December 31, 2008.
"Since July 2008, MDRNA has made significant strides in its
transition from a clinical stage intranasal drug delivery company to
an RNAi drug discovery company," stated J. Michael French, President
& CEO of MDRNA. "In the second half of 2008, we reduced headcount,
terminated all legacy intranasal clinical programs; close... |
| | | 03/23/09 | MDRNA Announces Worldwide Non-Exclusive Licensing Agreement for RNAi Delivery Technology| BOTHELL, WA, Mar 23, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has entered into
a licensing agreement with Novartis for MDRNA's liposomal technology
platform for siRNA delivery. MDRNA will receive $7.25 million in
upfront fees for the non-exclusive license. Additionally, the
companies have entered into a separate agreement, which provides
Novartis with an exclusive period to negotiate a research and
development collaboration and broader licensing r... |
| | | 03/20/09 | MDRNA, Inc. to Hold Year-End 2008 Earnings Conference on Tuesday, March 24, 2009, at 8:30 a.m. Eastern Time| BOTHELL, WA, Mar 20, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a
conference call with investors and security analysts on Tuesday,
March 24, 2009, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to
discuss financial results for the fourth quarter and fiscal year
ended December 31, 2008. To participate in the live conference call,
U.S. residents should dial 866-356-4441 and international callers
should dial 617-597-5396. The participant ... |
| | | 03/06/09 | MDRNA, Inc. Receives Delisting Notice From NASDAQ and Requests Hearing| BOTHELL, WA, Mar 06, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it received a NASDAQ
Staff Determination on March 4, 2009 indicating that the Company has
not regained compliance with Marketplace Rule 4450(a)(3) within the
extension period granted to the Company through March 3, 2009.
Marketplace Rule 4450(a)(3) requires a minimum $10.0 million in
stockholders' equity for continued listing on The NASDAQ Global
Market. In response to the March 4th letter... |
| | | 02/23/09 | MDRNA Successfully Silences Gene Targets in Animal Models Using Novel UsiRNA Constructs| Proprietary DiLA2 Platform Achieves In Vivo Knockdown of Multiple Metabolic Targets and Demonstrates Safe and Effective Delivery in Repeat Dose StudiesBOTHELL, WA, Feb 23, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today positive in vivo efficacy
data on its proprietary UsiRNA constructs demonstrating a dose
response which resulted in up to 90% knockdown of ApoB message in a
rodent model. The data were presented by Michael V. Templin, Ph.D.,
Vice President, Discove... |
| | | 02/13/09 | MDRNA, Inc. Announces Licensing Agreement With Roche| BOTHELL, WA, Feb 13, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has entered into
an agreement with Roche (SWX: ROG) in which Roche will obtain a
non-exclusive license to a portion of MDRNA's technology platform for
the development of RNAi-based therapeutics. Terms of the agreement
were not disclosed.
"We are pleased to have Roche recognize the value of our drug
discovery platform," stated J. Michael French, President and Chief
Executive Officer of ... |
| | | 02/03/09 | MDRNA, Inc. Announces Receipt of Milestone Payment Under Amended Agreement With Amylin Pharmaceuticals, Inc. for Development and Commercialization of Intranasal Exenatide| MDRNA Continues to Monetize Intranasal Assets to Support On-Going RNAi-Based Therapeutic R&DBOTHELL, WA, Feb 03, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today the achievement of a
milestone under an amended version of the June 2006 Development and
License Agreement with Amylin Pharmaceuticals, Inc. for the
development of intranasal exenatide. Under terms of the amended
agreement, Amylin has committed to advancing the program, resulting in
an accelerated $1 mill... |
| |
|
|
|
